Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Med Mycol ; 56(1): 29-43, 2018 Jan 01.
Article in English | MEDLINE | ID: mdl-28431008

ABSTRACT

Mucormycosis is an emerging infectious disease with high rates of associated mortality and morbidity. Little is known about the characteristics of mucormycosis or entomophthoromycosis occurring in Mexico. A search strategy was performed of literature published in journals found in available databases and theses published online at Universidad Nacional Autónoma de México (UNAM) library website reporting clinical cases or clinical case series of mucormycosis and entomophthoromycosis occurring in Mexico between 1982 and 2016. Among the 418 cases identified, 72% were diabetic patients, and sinusitis accounted for 75% of the reported cases. Diabetes mellitus was not a risk factor for entomophthoromycosis. Mortality rate was 51% (125/244). Rhizopus species were the most frequent isolates (59%, 148/250). Amphotericin B deoxycholate was used in 89% of cases (204/227), while surgery and antifungal management as combined treatment was used in 90% (172/191). In diabetic individuals, this combined treatment approach was associated with a higher probability of survival (95% vs 66%, OR = 0.1, 95% CI, 0.02-0.43' P = .002). The most common complications were associated with nephrotoxicity and prolonged hospitalization due to IV antifungal therapy. An algorithm is proposed to establish an early diagnosis of rhino-orbital cerebral (ROC) mucormycosis based on standardized identification of warning signs and symptoms and performing an early direct microbiological exam and histopathological identification through a multidisciplinary medical and surgical team. In summary, diabetes mellitus was the most common risk factor for mucormycosis in Mexico; combined antifungal therapy and surgery in ROC mucormycosis significantly improved survival.


Subject(s)
Diabetes Complications/diagnosis , Diabetes Complications/epidemiology , Disease Management , Mucormycosis/diagnosis , Mucormycosis/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Antifungal Agents/therapeutic use , Child , Child, Preschool , Debridement , Diabetes Complications/mortality , Diabetes Complications/therapy , Female , Hospitalization , Humans , Infant , Infant, Newborn , Length of Stay , Male , Mexico/epidemiology , Middle Aged , Mucorales/classification , Mucorales/isolation & purification , Mucormycosis/mortality , Mucormycosis/therapy , Prevalence , Survival Analysis , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL